Treatment of Paraneoplastic Cerebellar Degeneration in Rapidly Progressive Cerebellar Syndrome with Antineuronal Antibodies Against Intracellular Antigens
Clinical Scenario
This protocol applies to patients presenting with a rapidly progressive cerebellar syndrome in whom antineuronal antibodies directed against intracellular antigens have been detected. The identification of this antibody subclass has direct implications for which therapeutic approach is appropriate.
When detected antibodies target intracellular antigens specifically, regimens addressing T-cell–based immune mechanisms may offer a particular advantage over other immunotherapy approaches.
Treatment Approach Partial overview
The protocol coordinates two simultaneous priorities: early treatment of the underlying tumor — with the specific oncological modality determined by tumor type, staging, and individual patient factors — alongside first-line acute immunotherapy. Clinical goals are to reduce brain inflammation and lower levels of circulating antibodies. The complete regimen, escalation criteria, and sequencing are available in the full protocol.
References
DOI: 10.3390/brainsci11111414
- If a specific antibody has been detected, one can distinguish between antibodies directed against intracellular antigens and antibodies directed against cell-surface antigens.
- In the first case, regimens targeting T-cell based mechanisms might be of advantage.
- If a patient presents with a typical clinical syndrome and specific antineuronal antibodies are detected or suspected, acute therapeutical settings aim to reduce brain inflammation and levels of circulating antibodies.
- In most cases, treatment of the underlying oncological disorder is paramount for the treatment of the paraneoplastic syndrome as well.
- Of course, choice of oncological treatment options (surgery, chemotherapy, radiotherapy) depends on tumor entity, staging, and individual aspects.
View source ↗